Toripalimab not checked

Coherus Oncology, Inc. · JS001 · TAB-001

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 2 trial completes
Trials
7 active
10 in total · 3 in the EU
Targets
 

What this is

How it works
Releases a brake on the immune system (PD-1 or PD-L1) so it attacks cancer cells.Programmed Death Receptor-1 Blocking Antibody FDA class
How it’s given
“Participants will receive toripalimab via intravenous infusion (IV) on Day 1 every 3 weeks (Q3W) during the Chemotherapy-based treatment phase and Maintenance treatment phase.”In the company’s words, NCT06457503 on ClinicalTrials.gov
Tested for
Advanced Solid Tumor (2 trials), Nasopharyngeal Cancer Recurrent, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma, Metastatic Solid Tumor, Advanced or Metastatic Solid Tumors
Main trialPhase 4
“This study aims to investigate toripalimab with chemotherapy in participants with nasopharyngeal cancer.”In the company’s words, NCT06457503 on ClinicalTrials.gov
Other names
JS001 · TAB-001 · CHS-007 · Loqtorzi · TAB001

Other drugs for Advanced Solid Tumor

All 2438 drugs for Advanced Solid Tumor

Coming up4

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials10

TrialPhaseCompletesWhat it tests
Phase 4Recruiting Dec 2027 A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
Phase 2Active, not recruiting Sep 2027 A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
Phase 1Active, not recruiting 30 Sep 2026 Study of CHS-114 in Participants With Advanced Solid Tumors
Phase 1Recruiting Jan 2028 A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Phase 1Not yet recruiting 30 May 2028 A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors
Phase 1Terminated 31 Jul 2024 Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors
Phase 1Completed 28 May 2025 Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Phase 3Authorised not given A Randomized, Double-Blind, Placebo-Controlled, Multi-Regional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy
Phase 3Ended not given A prospective, randomized, placebo-controlled, double-blind, multicenter phase III registration clinical study to compare toripalimab (JS001) combined with lenvatinib versus placebo combined with lenvatinib as the 1st-line therapy for advanced hepatocellular carcinoma (HCC)
Phase 3Authorised not given Toripalimab plus chemotherapy as first-line treatment for recurrent and/or metastatic nasopharyngeal cancer: safety and activity in non-endemic population
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Toripalimab

Following is part of Solo: you see every change to Toripalimab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in